Tesamorelin

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH (1-44) with a trans-3-hexenoic acid modification at the N-terminal tyrosine residue. ^(1,2) This modification provides greater resistance to enzymatic degradation compared to endogenous GHRH, improving metabolic stability and extending the peptide’s effective duration. The molecular weight of tesamorelin acetate (free base) is approximately 5,135.9 daltons. ⁽¹⁾

Tesamorelin occupies a unique position among research peptides: it is the only GHRH analog approved by the FDA. The peptide was originally approved in November 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and it remains the only medication approved in the United States for this indication. ^(1,3) In March 2025, the FDA approved the Egrifta WR formulation (tesamorelin F8), an improved version requiring only weekly reconstitution and less than half the injection volume of its predecessor (Egrifta SV), while maintaining bioequivalence to the original formulation. ⁽³⁾

Unlike exogenous human growth hormone (HGH), which floods the system with synthetic GH and suppresses the body’s own production, tesamorelin works upstream by stimulating the pituitary gland to release growth hormone in its natural pulsatile pattern. ^(1,2) This preserves the somatostatin negative feedback loop, the body’s built-in brake on GH secretion, reducing the risk of supraphysiological GH and IGF-1 levels that are associated with exogenous HGH use. ⁽²⁾ This distinction is critical for understanding tesamorelin’s safety profile and why it has attracted such extensive research interest.

The FDA-approved clinical indication is specific to HIV-associated lipodystrophy. Use of tesamorelin for general fat loss, body composition optimization (also spelled optimization), anti-aging (also spelled anti-aging), or performance purposes is considered off-label and is not FDA-sanctioned. ⁽¹⁾ Outside the United States, tesamorelin has not been approved by the MHRA (UK) or the TGA (Australia) for any therapeutic indication. It is available as a research peptide for laboratory and investigational use.

Healius supplies tesamorelin as a lyophilized (also referred to as lyophilized) powder in 5mg vials, intended strictly for laboratory and research applications.

Tesamorelin exerts its biological effects by binding to and activating GHRH receptors located on somatotroph cells in the anterior pituitary gland. In vitro studies have demonstrated that tesamorelin binds and stimulates human GRF receptors with a potency similar to that of endogenous GHRH. ^(1,2)

Upon receptor binding, tesamorelin activates intracellular signaling cascades, primarily involving cyclic adenosine monophosphate (cAMP), which stimulates the synthesis and pulsatile release of endogenous growth hormone. ^(1,2) The released GH then circulates to target tissues throughout the body, where it binds to GH receptors and triggers a cascade of downstream effects. In the liver, GH stimulates the production and secretion of insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3), which mediate many of GH’s anabolic and metabolic effects. ⁽²⁾

The key metabolic effect of tesamorelin-stimulated GH release is the activation of hormone-sensitive lipase in adipocytes, enhancing lipolysis (fat breakdown) and fatty acid oxidation. ^(1,2) What distinguishes tesamorelin from general lipolytic agents is its selectivity for visceral adipose tissue (VAT), the metabolically active fat surrounding internal organs, rather than subcutaneous fat beneath the skin. ^(4,5) This selectivity has been demonstrated in Phase III clinical trials using CT imaging, which showed significant reductions in VAT with minimal effects on subcutaneous fat depots. ^(4,5)

GH also acts directly on target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, producing a range of pharmacodynamic effects, including increased protein synthesis, enhanced nitrogen retention, and improved cellular repair. ⁽¹⁾ These effects explain the broader research interest in tesamorelin beyond its approved HIV-lipodystrophy indication.

A critical pharmacological feature is the preservation of the somatostatin feedback mechanism. When GH levels rise following tesamorelin administration, somatostatin release from the hypothalamus increases, providing a natural ceiling on GH secretion. ⁽²⁾ This self-regulating mechanism means that tesamorelin-stimulated GH release does not typically reach the supraphysiological levels associated with exogenous HGH injection, resulting in a more favorable safety profile for sustained use. ⁽²⁾

Tesamorelin has one of the strongest evidence bases among research peptides, with Phase III randomized controlled trial data from over 800 patients and more than a decade of post-market clinical experience. ^(4,5)

The pivotal Phase III clinical trials (LIPO-010 and CTR-1011) enrolled 806 HIV-infected patients with excess abdominal fat and evaluated tesamorelin against placebo over 26 weeks. ^(4,5) Treatment with tesamorelin produced a 15-18% reduction in visceral adipose tissue as measured by CT imaging, a clinically meaningful change in a metabolically dangerous fat depot that is resistant to diet and exercise alone. ^(4,5) Patients also showed improvements in trunk fat, waist circumference, and triglyceride levels. Importantly, the reduction was specific to visceral fat; subcutaneous fat and lean muscle mass were largely preserved. ^(4,5) These trials formed the basis for FDA approval and represent the most rigorous clinical evidence for any GH-related peptide.

The STAY study (Stanley et al., 2019) investigated tesamorelin’s effects on cognitive function in HIV-positive older adults over 12 months. ⁽⁷⁾ The study demonstrated preservation of cognitive function in treated subjects compared to controls, opening a new avenue of investigation for tesamorelin in age-related cognitive decline. This cognitive dimension is particularly relevant given that GH and IGF-1 have established roles in neuronal health, synaptic plasticity, and neuroprotection. ⁽⁷⁾

Tesamorelin has been investigated for nonalcoholic fatty liver disease (NAFLD), a condition characterized by excess fat accumulation in the liver that affects an estimated 25-30% of the global population. ⁽⁶⁾ Research has demonstrated that tesamorelin reduces hepatic fat fraction in HIV-infected patients with NAFLD, with effects mediated through the GH/IGF-1 axis. Given the limited pharmacotherapy options for NAFLD, this represents a significant area of ongoing investigation. ⁽⁶⁾

Beyond visceral fat, metabolic research has examined tesamorelin’s effects on lipid profiles, insulin sensitivity, inflammatory markers, and body composition. The combination of visceral fat reduction, improved triglycerides, and preserved lean mass has positioned tesamorelin as a compound of particular interest in cardiometabolic risk research.

Regarding the highly searched “before and after” query: the Phase III clinical trial data provides the most reliable evidence base. The 15-18% reduction in visceral fat measured by CT imaging over 26 weeks in 806 patients represents standardized, peer-reviewed outcomes. ^(4,5) Individual results in off-label contexts vary significantly based on dosing, treatment duration, diet, exercise, and baseline body composition. Anecdotal before-and-after reports circulating online lack the controlled conditions of the clinical trial data.

The comparison between tesamorelin and sermorelin is among the most frequently searched topics in the GH peptide space, and the differences between these two GHRH analogs are substantial enough to significantly influence protocol design. ⁽⁸⁾

Tesamorelin is a synthetic analog of the full 44-amino-acid GHRH (1-44) sequence, with an N-terminal hexenoic acid modification to enhance stability. ⁽¹⁾ It is the only GHRH analog with FDA approval, supported by Phase III clinical trial data from over 800 patients demonstrating 15-18% visceral fat reduction. ^(4,5) Its primary research application centers on visceral fat metabolism, body composition, and cardiometabolic risk.

Sermorelin is a truncated GHRH analog consisting of only the first 29 amino acids of GHRH (1-29). It was FDA-approved in the 1990s for the diagnosis and treatment of GH deficiency in children (under the brand name Geref). Still, this approval was subsequently discontinued due to manufacturing issues, not safety concerns. ⁽⁸⁾ Sermorelin has a shorter half-life and lower potency than tesamorelin, and it lacks Phase III clinical trial data for visceral fat reduction.

The practical differences for researchers: tesamorelin offers a stronger evidence base, greater GHRH receptor potency, improved metabolic stability due to its hexenoic acid modification, and demonstrated visceral fat selectivity, as supported by CT imaging data. Sermorelin offers a lower cost point, a longer history of off-label use, and may be appropriate for research contexts where maximal GH stimulation is not required. Both peptides stimulate pulsatile GH release and preserve the somatostatin feedback loop, distinguishing them from exogenous HGH.

For researchers investigating visceral fat metabolism, NAFLD, or body composition changes, tesamorelin’s Phase III data provides a more robust evidence base for protocol design. For researchers investigating general GH deficiency markers, sleep quality, or baseline GH restoration at a lower cost, sermorelin remains a widely studied option.

Understanding how tesamorelin compares to other GH-related peptides helps researchers select the most appropriate compound for their study objectives. The key distinction lies in where each peptide acts within the GH/IGF-1 axis. ^(2,9)

Tesamorelin is a GHRH analog that acts at the pituitary level, stimulating GH synthesis and release through GHRH receptors. Ipamorelin is a growth hormone-releasing peptide (GHRP) that also acts at the pituitary level, but through a different receptor: the ghrelin/GHS receptor (GHS-R1a). ⁽⁹⁾ The distinction matters because GHRH and GHRP pathways are synergistic. GHRH sets the amplitude of GH pulses, while GHRPs increase the frequency of GH pulses. Combining a GHRH analog (like tesamorelin or CJC-1295) with a GHRP (like ipamorelin) produces a synergistic GH response greater than either compound alone. ⁽⁹⁾

CJC-1295 (also known as Mod GRF 1-29 in its non-DAC form) is another GHRH analog based on the truncated GHRH (1-29) sequence, with amino acid substitutions to improve stability. The CJC-1295 + Ipamorelin blend is one of the most commonly researched GH-releasing combinations that pair the GHRH and GHRP pathways. Tesamorelin differs from CJC-1295 in that it uses the full-length GHRH (1-44) sequence with a hexenoic acid modification rather than amino acid substitutions, and it has the advantage of FDA approval and Phase III clinical data.

Compared to exogenous HGH, tesamorelin preserves the body’s natural pulsatile GH secretion pattern and somatostatin feedback loop. ⁽²⁾ HGH delivers a bolus of synthetic growth hormone that bypasses the pituitary entirely, producing sustained supraphysiological GH levels that suppress endogenous production. Tesamorelin’s approach is considered more physiologically conservative, though the GH levels achieved are generally lower than those achieved with HGH injections.

Compared to IGF-1 LR3, which acts downstream by directly activating IGF-1 receptors, tesamorelin acts far upstream by stimulating the pituitary to produce GH, which then stimulates hepatic IGF-1 production through the natural pathway. IGF-1 LR3 produces more potent, direct receptor activation but carries greater risks (hypoglycemia, unregulated cell proliferation). Tesamorelin produces more moderate, physiologically regulated effects with a better-characterized safety profile. ⁽²⁾

Regarding retatrutide (the triple GIP/GLP-1/glucagon receptor agonist), which is a separate class of compound entirely, tesamorelin and Retatrutide operate through completely different mechanisms. Tesamorelin stimulates GH release, reducing visceral fat. Retatrutide targets metabolic hormone receptors involved in appetite regulation, glucose metabolism, and energy expenditure. They address body composition through different physiological pathways.

1. FDA Prescribing Information. EGRIFTA WR (tesamorelin for injection). Full prescribing information, including mechanism, dosage, contraindications, warnings, adverse reactions, and clinical trial data. Updated 2025. accessdata.fda.gov.

2. DrugBank / LiverTox NCBI. Tesamorelin mechanism of action: GHRH receptor binding on anterior pituitary somatotroph cells, cAMP signaling cascade, pulsatile GH release, and somatostatin feedback preservation.

3. Theratechnologies Inc. Press release: FDA approval of EGRIFTA WR (tesamorelin F8) for treatment of excess visceral abdominal fat in adults with HIV and lipodystrophy. March 25, 2025. Globe Newswire.

4. Phase III Clinical Trial LIPO-010. Tesamorelin for the reduction of visceral adipose tissue in HIV-infected patients with lipodystrophy. 806 patients, 26-week randomized controlled trial. 15-18% VAT reduction by CT imaging.

5. Phase III Clinical Trial CTR-1011. Confirmatory trial of tesamorelin for HIV-associated lipodystrophy. Consistent with LIPO-010 findings on visceral fat reduction, trunk fat, and triglyceride improvements.

6. Tesamorelin research in NAFLD (nonalcoholic fatty liver disease). Demonstrated reduction in hepatic fat fraction in HIV-infected patients. Referenced in multiple hepatology and endocrinology reviews.

7. Stanley TL, et al. The STAY Study: Tesamorelin effects on cognitive function in HIV-positive older adults over 12 months. Published 2019. Demonstrated preservation of cognitive function in treated subjects.

8. Sermorelin: truncated GHRH (1-29) analog. Previously FDA-approved (Geref) for GH deficiency diagnosis/treatment in children; approval subsequently discontinued due to manufacturing issues.

9. GHRH-GHRP synergy: GHRH sets GH pulse amplitude; GHRPs (ipamorelin, GHRP-2, GHRP-6) increase GH pulse frequency. Co-administration produces a synergistic GH response. Referenced in multiple GH peptide pharmacology reviews.

10. WADA Prohibited List 2026. Tesamorelin is prohibited under S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics: at all times, in-competition and out-of-competition.

11. PeptideWiki Editorial Team. Tesamorelin Dosage Guide: FDA-Approved Protocols & Research. February 2026. Compiled dosing, reconstitution, timing, cycling, and stacking protocols.

12. Contagion Live. FDA Approves F8 Formulation of Theratechnologies’ Tesamorelin for HIV-Associated Lipodystrophy. March/April 2025.

13. Paragon Sports Medicine. Tesamorelin Peptide: Metabolic & Fat Balance. Comprehensive review of mechanism, clinical applications, selectivity for visceral adipose tissue, and safety profile. 2025.

14. Women’s Health of Maryland. Tesamorelin Peptide Therapy overview: GHRH receptor mechanism, visceral fat selectivity, clinical trial evidence, off-label considerations. 2025-2026.

This product is sold strictly for laboratory and research use only. It is not intended for human or animal consumption. It is not a dietary supplement, food, drug, or cosmetic. It is not intended to diagnose, treat, cure, or prevent any disease or condition. The buyer assumes all responsibility for the lawful use of this product in accordance with all applicable local, state, national, and international laws and regulations. By purchasing this product, the buyer confirms that they are a qualified researcher or are purchasing on behalf of a research institution.